DEA Rescheduling Legal Challenge: Constitutional Questions and Court Review

Executive Summary

The D.C. Circuit Court of Appeals is now deciding whether the DEA's proposed rescheduling of cannabis from Schedule I to Schedule III violated constitutional separation-of-powers principles—a question Yale Law Journal scholars warned about years before the agency initiated its historic rulemaking. The legal challenge, filed by multiple stakeholders including state-licensed operators, patients, and advocacy organizations, argues that the DEA improperly delegated its statutory authority under the Controlled Substances Act to the Department of Health and Human Services, allowing HHS to effectively dictate scheduling outcomes without independent DEA scientific review. At stake is not only the validity of the largest proposed drug rescheduling in five decades, but the fundamental architecture of federal drug policy authority established by Congress in 1970. The case consolidates claims that the DEA violated the Administrative Procedure Act, exceeded its statutory mandate under 21 U.S.C. § 811, and improperly deferred to HHS recommendations without conducting the independent eight-factor analysis required by law. Oral arguments concluded in June 2026, with a decision expected by October 2026 that could reshape federal cannabis regulation or send the entire rescheduling process back to square one.

Why This Matters

This litigation affects $33 billion in annual U.S. cannabis sales, approximately 15,000 state-licensed businesses, 800,000 industry employees, and millions of medical cannabis patients across 38 states. The outcome will determine whether the DEA's proposed move of cannabis to Schedule III proceeds—a change that would eliminate the punitive Internal Revenue Code Section 280E tax burden that currently prevents cannabis businesses from deducting ordinary business expenses. Industry analysts estimate 280E relief alone would save multi-state operators between $1.2 billion and $1.8 billion annually in federal tax liability.

Beyond immediate financial implications, the case establishes precedent for how federal agencies can interact when making scheduling decisions for controlled substances. If the D.C. Circuit rules that the DEA improperly delegated its authority to HHS, the decision could invalidate not only the cannabis rescheduling but potentially dozens of other scheduling actions taken over the past two decades where similar deference patterns occurred.

For patients, the stakes are equally high. Schedule III status would maintain federal prohibition while theoretically allowing limited research expansion and potential FDA approval pathways for cannabis-derived medications. However, it would not resolve the conflict between state medical programs and federal law, leaving patients in legal limbo. Patient advocacy groups have filed amicus briefs on both sides—some supporting rescheduling as incremental progress, others opposing it as insufficient and legally flawed.

The pharmaceutical industry is watching closely. Schedule III classification would subject cannabis to FDA drug approval requirements while potentially opening pathways for pharmaceutical companies to develop and patent specific formulations, a prospect that alarms advocates who fear corporate capture of a plant-based medicine.

Background and History

The constitutional separation of drug scheduling powers has been contested since Congress enacted the Controlled Substances Act in 1970, but the current crisis emerged from a 2022 presidential directive that set in motion the largest proposed rescheduling in federal history.

The Controlled Substances Act Framework (1970)

Congress established the modern drug scheduling system through the Controlled Substances Act, codified at 21 U.S.C. § 801 et seq. The statute created five schedules of controlled substances based on medical utility, abuse potential, and safety profile. Section 811 assigned the Attorney General—who delegated authority to the DEA—responsibility for adding, removing, or transferring drugs between schedules. However, the statute required the Attorney General to "request from the Secretary of Health and Human Services a scientific and medical evaluation" before initiating any scheduling action.

This bifurcated structure created inherent tension. The DEA, a law enforcement agency within the Department of Justice, received ultimate scheduling authority. But HHS, through the Food and Drug Administration, controlled the scientific evaluation process. The statute specified eight factors the Attorney General must consider, including actual or relative potential for abuse, scientific evidence of pharmacological effect, current scientific knowledge, history and current pattern of abuse, scope and significance of abuse, and risk to public health.

Cannabis was placed in Schedule I—the most restrictive category, reserved for substances with high abuse potential, no accepted medical use, and lack of accepted safety for use under medical supervision. This classification occurred despite the 1972 Shafer Commission recommendation that Congress decriminalize personal cannabis possession.

The Yale Law Journal Warning (2015)

In a 2015 Yale Law Journal article, legal scholars examined the evolving relationship between DEA and HHS in scheduling decisions. The analysis warned that the statutory separation of powers was "collapsing" as the DEA increasingly rubber-stamped HHS scientific recommendations without conducting independent analysis. The article documented cases where the DEA adopted HHS conclusions verbatim, raising questions about whether the agency was fulfilling its statutory obligation to independently evaluate the eight factors under 21 U.S.C. § 811(c).

The scholars identified a pattern: HHS would conduct extensive scientific review, issue a binding recommendation, and the DEA would defer without meaningful independent evaluation. This effectively transferred scheduling authority from the law enforcement agency Congress designated to the public health agency Congress assigned only an advisory role.

Biden Administration Directive (October 2022)

On October 6, 2022, President Joe Biden issued a directive instructing the Attorney General and the Secretary of HHS to "expeditiously" review how cannabis is scheduled under federal law. The presidential memorandum cited changing state laws, evolving scientific understanding, and concerns about criminal justice impacts of current policy.

The directive set in motion an unprecedented process. HHS Secretary Xavier Becerra tasked the FDA with conducting a comprehensive scientific review of cannabis. The FDA assembled a team that examined clinical studies, state medical program data, epidemiological research on abuse patterns, and international scientific literature.

HHS Recommendation (August 2023)

On August 29, 2023, HHS delivered its recommendation to the DEA: move cannabis from Schedule I to Schedule III. The recommendation relied heavily on FDA analysis concluding that cannabis has accepted medical use in the United States, citing state medical programs serving millions of patients and emerging clinical evidence for conditions including chronic pain, chemotherapy-induced nausea, and multiple sclerosis spasticity.

The HHS recommendation was binding under the statutory framework for the question of scientific and medical evaluation. However, the DEA retained authority to consider additional factors including international treaty obligations, enforcement considerations, and regulatory feasibility.

DEA Notice of Proposed Rulemaking (May 2024)

On May 16, 2024, the DEA published a Notice of Proposed Rulemaking in the Federal Register proposing to reschedule cannabis to Schedule III. The 466-page document outlined the agency's analysis of the eight statutory factors. The DEA opened a 60-day comment period, later extended to 90 days, that ultimately generated more than 43,000 public submissions—the most in DEA rulemaking history.

The NPRM acknowledged the HHS recommendation but stated the DEA had conducted its own independent review. However, critics immediately noted that large sections of the DEA's analysis mirrored HHS language, and the agency appeared to adopt HHS conclusions on medical utility without conducting original research or analysis.

Administrative Law Judge Hearing (December 2024 - February 2025)

Under the Controlled Substances Act, any interested party can request a hearing before an Administrative Law Judge to contest a proposed scheduling action. More than 30 parties requested hearings, including state attorneys general, cannabis industry associations, patient advocacy groups, law enforcement organizations, and anti-legalization groups like Smart Approaches to Marijuana.

The DEA consolidated the requests and assigned ALJ Catherine Reuben to preside over hearings held in Washington, D.C. from December 2024 through February 2025. Witnesses included pharmacologists, physicians, state regulators, DEA chemists, and policy experts. A central theme emerged: whether the DEA had genuinely conducted independent analysis or simply deferred to HHS.

ALJ Reuben issued her recommended decision in April 2025, finding that the DEA had adequately justified the rescheduling under the Administrative Procedure Act. However, she noted concerns about the degree of deference to HHS and recommended the DEA provide additional explanation of its independent analysis in the final rule.

Final Rule and Legal Challenges (September 2025)

The DEA published its final rule on September 12, 2025, rescheduling cannabis to Schedule III effective November 1, 2025. The rule made minor modifications based on public comments but largely adopted the proposed approach. Within hours, multiple parties filed petitions for review in the D.C. Circuit Court of Appeals, the exclusive venue for challenges to DEA scheduling decisions under 21 U.S.C. § 877.

The court consolidated the cases under the caption Coalition for Cannabis Scheduling Reform v. Drug Enforcement Administration. Lead petitioners included the U.S. Cannabis Council, Americans for Safe Access, the Marijuana Policy Project, and several multi-state operators. Intervenors supporting the DEA included the American Medical Association and several pharmaceutical companies. Intervenors opposing the rule from the other direction included Smart Approaches to Marijuana, arguing cannabis should remain Schedule I.

Key Players

Drug Enforcement Administration

The DEA, led by Administrator Anne Milgram, is the defendant in the consolidated litigation. The agency has defended its rescheduling decision as based on thorough independent analysis of the eight statutory factors. DEA attorneys argue that while the agency gave substantial weight to HHS scientific expertise, it conducted its own evaluation of enforcement data, international treaty obligations, and regulatory considerations. The DEA maintains it fulfilled its statutory mandate under 21 U.S.C. § 811 and complied with Administrative Procedure Act requirements for reasoned decision-making.

Department of Health and Human Services

HHS, through the FDA, conducted the scientific and medical evaluation that recommended Schedule III. Secretary Becerra has defended the recommendation as based on rigorous scientific review. HHS officials have testified that the agency examined more than 3,200 peer-reviewed studies, analyzed data from 38 state medical cannabis programs, and consulted with international health authorities. The department argues its role is purely advisory and that the DEA retained full authority to accept or reject the recommendation.

Coalition for Cannabis Scheduling Reform

This umbrella organization represents the lead petitioners challenging the rescheduling. The coalition includes the U.S. Cannabis Council, representing multi-state operators with combined annual revenue exceeding $8 billion; Americans for Safe Access, a patient advocacy organization with 100,000 members; and the Marijuana Policy Project. The coalition's legal team, led by former Solicitor General Donald Verrilli, argues the DEA violated separation-of-powers principles by improperly delegating its statutory authority to HHS.

Smart Approaches to Marijuana

SAM, led by co-founder Kevin Sabet, intervened in the litigation to argue cannabis should remain in Schedule I. The organization contends that state medical programs do not constitute "accepted medical use" under the statutory standard, which requires FDA approval through the drug development process. SAM has filed briefs arguing the DEA's decision was arbitrary and capricious because it relied on state programs that lack the scientific rigor of FDA clinical trials.

American Medical Association

The AMA intervened supporting the DEA's rescheduling decision. The organization, representing more than 270,000 physicians, filed an amicus brief arguing that emerging clinical evidence supports medical utility for specific conditions and that Schedule III classification would facilitate necessary research while maintaining appropriate controls. The AMA has advocated for cannabis rescheduling since 2009.

Multi-State Operators

Companies including Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs have significant financial stakes in the outcome. These MSOs collectively operate more than 800 dispensaries across multiple states and generate billions in annual revenue. Industry representatives have emphasized that Schedule III status would provide 280E tax relief while maintaining state-legal operations, though it would not resolve fundamental federal-state conflicts.

Legal and Regulatory Framework

The litigation centers on interpretation of the Controlled Substances Act's scheduling provisions, Administrative Procedure Act standards for agency decision-making, and constitutional separation-of-powers doctrine.

Controlled Substances Act Section 811

The statutory text of 21 U.S.C. § 811 assigns the Attorney General authority to schedule controlled substances but requires requesting scientific evaluation from HHS. Subsection (b) states that HHS recommendations on scientific and medical matters are binding on the Attorney General "as to such matters." However, subsection (c) requires the Attorney General to consider eight specific factors, only some of which fall within HHS scientific expertise.

Petitioners argue this structure requires the DEA to conduct independent analysis of all eight factors, not simply defer to HHS on matters the health agency deems scientific. The DEA counters that it fulfilled this obligation by evaluating enforcement data, international treaties, and regulatory considerations beyond HHS expertise.

Administrative Procedure Act Section 706

Under 5 U.S.C. § 706, courts review agency actions to determine whether they are arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law. The Supreme Court's decision in Motor Vehicle Manufacturers Association v. State Farm Mutual (1983) established that agencies must examine relevant data and articulate a rational connection between facts found and choices made.

Petitioners contend the DEA failed this standard by adopting HHS conclusions without independent analysis. They point to sections of the final rule that use identical language to the HHS recommendation, suggesting the agency did not genuinely grapple with the evidence. The DEA responds that agreement with expert scientific analysis does not constitute arbitrary decision-making.

Non-Delegation Doctrine

The constitutional challenge invokes the non-delegation doctrine, which prohibits Congress from transferring its legislative powers to executive agencies without providing an "intelligible principle" to guide agency discretion. Petitioners argue that even if Congress validly delegated scheduling authority to the DEA, the agency cannot sub-delegate that authority to HHS.

This argument faces significant headwinds. The Supreme Court has not invalidated a federal statute on non-delegation grounds since 1935, and the Controlled Substances Act's eight-factor framework likely provides sufficient guidance under current doctrine. However, the Court's recent skepticism toward broad agency authority in cases like West Virginia v. EPA (2022) has emboldened challenges to administrative power.

Treaty Obligations

The United States is party to three international drug control treaties: the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, and the 1988 Convention Against Illicit Traffic in Narcotic Drugs. These treaties require parties to limit cannabis to medical and scientific use and maintain criminal penalties for non-medical possession.

Schedule III classification maintains federal prohibition of non-medical use, arguably satisfying treaty obligations. However, the disconnect between federal Schedule III status and state recreational legalization in 24 states creates potential treaty compliance issues that the DEA addressed only briefly in its final rule.

State-by-State Breakdown

The rescheduling litigation intersects with a complex patchwork of state cannabis laws that created the factual predicate for HHS finding "accepted medical use."

California

California operates the nation's largest cannabis market, with medical use legal since 1996 under Proposition 215 and adult use since 2016 under Proposition 64. The state's Department of Cannabis Control oversees approximately 3,200 licensed businesses serving an estimated 6 million consumers annually. California regulators filed an amicus brief supporting rescheduling, arguing that the state's track-and-trace system and laboratory testing requirements demonstrate that medical cannabis can be safely regulated. The state's medical program allows possession of up to eight ounces and cultivation of up to six mature plants for qualified patients.

Florida

Florida's medical cannabis program, established by constitutional amendment in 2016, serves more than 800,000 registered patients—the second-largest medical program nationally. The state's vertical integration requirement, which mandates that licensees handle cultivation, processing, and retail, created the business model that multi-state operators now use nationwide. Florida's Office of Medical Marijuana Use submitted data to the FDA showing that registered patients use cannabis for conditions including cancer, epilepsy, glaucoma, HIV/AIDS, PTSD, ALS, Crohn's disease, Parkinson's disease, and multiple sclerosis. Possession limits reach up to 2.5 ounces per 35-day period for smokable cannabis.

New York

New York legalized medical cannabis in 2014 and adult use in 2021. The state's Office of Cannabis Management regulates a market projected to reach $1.3 billion in medical sales by 2027. New York's medical program emphasizes serious conditions and requires physician certification rather than traditional prescription. The state allows possession of up to 60-day supply as determined by the certifying physician. New York Attorney General Letitia James filed comments during the NPRM period supporting rescheduling as consistent with state regulatory experience.

Texas

Texas operates a limited medical program restricted to low-THC cannabis (0.5% THC or less) for specific conditions including epilepsy, terminal cancer, and PTSD. The state's Compassionate Use Program serves approximately 50,000 registered patients. Texas did not participate in the rescheduling litigation, but the state's restrictive approach illustrates the variation in what constitutes "accepted medical use" across jurisdictions. Possession limits are determined by physician prescription, typically 90-day supplies.

Ohio

Ohio's medical cannabis program, launched in 2019, serves approximately 250,000 registered patients. The state's Board of Pharmacy regulates dispensaries while the Department of Commerce oversees cultivation and processing. Ohio allows possession of up to 90-day supply, defined as 26,000 milligrams of THC. The state submitted data to the FDA showing patient use for chronic pain, PTSD, inflammatory bowel disease, and other qualifying conditions. Ohio voters approved adult-use legalization in November 2023, with sales beginning in 2024.

Massachusetts

Massachusetts legalized medical cannabis in 2012 and adult use in 2016. The state's Cannabis Control Commission oversees a unified regulatory framework for both markets. Medical patients can possess up to 10 ounces and cultivate up to 12 plants. Massachusetts requires all cannabis products undergo testing for potency, pesticides, heavy metals, and microbial contamination—standards the FDA cited as evidence that medical cannabis can meet safety requirements. The state's market generates approximately $1.5 billion in annual sales across both medical and adult-use channels.

Market and Business Implications

Schedule III classification would fundamentally alter cannabis industry economics through 280E tax relief while creating new regulatory obligations and competitive dynamics.

Internal Revenue Code Section 280E

The most immediate financial impact involves IRC § 280E, which prohibits businesses trafficking in Schedule I or Schedule II controlled substances from deducting ordinary business expenses. Cannabis companies currently can deduct only cost of goods sold, resulting in effective federal tax rates between 40% and 70% despite operating legally under state law.

Industry analysts project that Schedule III status would reduce effective tax rates to 25%-30%, saving multi-state operators between $1.2 billion and $1.8 billion annually. Curaleaf estimated in securities filings that 280E relief would improve its EBITDA by approximately $120 million annually. Trulieve projected $180 million in annual savings. These savings would flow directly to bottom lines, potentially triggering significant stock price appreciation for publicly traded operators.

Capital Markets Access

Schedule III status would not automatically grant cannabis companies access to traditional banking or national stock exchanges. The Bank Secrecy Act and anti-money laundering regulations would still classify cannabis proceeds as potentially suspicious because the underlying activity remains federally prohibited. Major banks have indicated they would not serve cannabis clients until Congress passes comprehensive reform legislation like the SAFER Banking Act.

However, Schedule III could influence Canadian stock exchanges and over-the-counter markets where U.S. cannabis companies currently trade. Reduced regulatory risk might attract institutional investors currently prohibited by compliance policies from investing in Schedule I-related businesses.

FDA Regulation and Pharmaceutical Competition

Schedule III substances require FDA approval for medical use, creating a potential pathway for pharmaceutical companies to develop cannabis-derived medications. Several major pharmaceutical firms have filed patents for specific cannabinoid formulations and delivery mechanisms. GW Pharmaceuticals (now part of Jazz Pharmaceuticals) already markets Epidiolex, an FDA-approved CBD medication for epilepsy.

Patient advocates fear that FDA regulation could lead to pharmaceutical companies capturing the medical cannabis market through patent protection and prescription requirements, potentially displacing state-licensed dispensaries. However, the DEA's final rule acknowledged that existing state medical programs would continue operating alongside any future FDA-approved products.

Interstate Commerce

Schedule III status would not legalize interstate cannabis commerce. Federal prohibition of non-medical use would continue, and state-licensed operators would still face restrictions on moving products across state lines. This maintains the current inefficient system where multi-state operators must build separate cultivation and processing facilities in each state rather than operating integrated national supply chains.

Some legal scholars argue that Schedule III classification could enable limited interstate commerce in cannabis for FDA-approved medical purposes, similar to how Schedule III substances like ketamine and anabolic steroids move between states for legitimate medical use. However, the DEA has not issued guidance on this question.

Wholesale Pricing and Market Consolidation

Tax savings from 280E relief would likely trigger price competition as operators with improved margins undercut competitors. Wholesale cannabis prices have already declined 40%-60% in mature markets like California and Oregon due to oversupply. Additional margin pressure from 280E relief could accelerate consolidation as smaller operators struggle to compete with well-capitalized MSOs.

Industry observers project that the top 10 multi-state operators would capture 60%-70% of the national market within three years of Schedule III implementation, up from approximately 45% currently. This consolidation would mirror patterns in other regulated industries like alcohol distribution and pharmaceutical retail.

What Experts Say

Legal scholars, industry analysts, and policy experts have offered sharply divergent assessments of the rescheduling litigation and its implications.

Robert Mikos, a law professor at Vanderbilt University and leading cannabis law scholar, said the DEA faces a difficult task defending its level of deference to HHS. According to Mikos, the statutory structure requires the DEA to conduct independent analysis even when agreeing with HHS scientific conclusions, and the agency's final rule may not adequately demonstrate that independent evaluation occurred.

John Hudak, a senior fellow at the Brookings Institution, said the litigation reflects broader tensions in administrative law about agency expertise and deference. According to Hudak, courts have traditionally granted agencies substantial leeway in interpreting their statutory mandates, but recent Supreme Court decisions suggest growing skepticism toward broad administrative authority that could influence the D.C. Circuit's analysis.

Alex Kreit, a professor at Thomas Jefferson School of Law, said the non-delegation challenge faces long odds given decades of precedent upholding the Controlled Substances Act's framework. According to Kreit, the more viable argument focuses on whether the DEA complied with Administrative Procedure Act requirements for reasoned decision-making rather than constitutional separation of powers.

Sam Kamin, a professor at the University of Denver Sturm College of Law, said the case highlights fundamental problems with the Controlled Substances Act's scheduling system. According to Kamin, the statute's binary framework—substances either have accepted medical use or they don't—cannot accommodate the complex reality of cannabis, which has demonstrated efficacy for some conditions while lacking the rigorous clinical trial data the FDA typically requires for drug approval.

Emily Kaltenbach, senior director of the Drug Policy Alliance, said patient advocates are divided on whether Schedule III represents progress or a dangerous compromise. According to Kaltenbach, some patients support rescheduling as incremental reform that could facilitate research, while others oppose it as entrenching federal prohibition and potentially enabling pharmaceutical industry capture of medical cannabis.

Kevin Sabet, president of Smart Approaches to Marijuana, said the DEA's decision ignores the statutory requirement that accepted medical use means FDA approval through controlled clinical trials. According to Sabet, state medical programs lack the scientific rigor necessary to establish medical utility under federal law, and the agency's reliance on state data was arbitrary and capricious.

Morgan Fox, political director of the National Organization for the Reform of Marijuana Laws, said the litigation distracts from the real solution: congressional action to deschedule cannabis entirely. According to Fox, rescheduling to Schedule III maintains federal prohibition and does nothing to protect state-legal operators or consumers from federal prosecution, making it an inadequate half-measure.

What's Next

The D.C. Circuit Court of Appeals is expected to issue its decision in Coalition for Cannabis Scheduling Reform v. DEA by October 2026, with several possible outcomes that would trigger different next steps.

If the court upholds the DEA's rescheduling decision, Schedule III status would take full effect, triggering 280E tax relief for the 2026 tax year. Multi-state operators would file amended returns claiming ordinary business expense deductions, potentially generating $1.5 billion in refunds for prior years where statutes of limitation remain open. The IRS would need to issue guidance on how cannabis businesses should calculate deductions under normal tax rules.

However, the losing parties would likely petition for rehearing en banc before the full D.C. Circuit, potentially delaying final resolution until 2027. If the full circuit declines rehearing, the losing side could petition the Supreme Court for certiorari. The Court grants review in only 1%-2% of petitions, but the case presents novel questions about agency authority that could attract the justices' interest, particularly given the Court's recent focus on limiting administrative power.

If the court invalidates the rescheduling on procedural grounds—finding the DEA failed to conduct adequate independent analysis—the agency would need to restart the process. This could involve reopening the comment period, conducting additional hearings, and issuing a new final rule with more detailed explanation of its independent evaluation. This scenario would delay Schedule III implementation by 18-24 months.

If the court invalidates the rescheduling on substantive grounds—finding that cannabis does not meet the statutory criteria for Schedule III—the DEA would face a choice: maintain Schedule I status, propose a different schedule, or recommend that Congress amend the Controlled Substances Act to create a new regulatory framework for cannabis.

Regardless of the litigation outcome, congressional action remains possible. The SAFER Banking Act, which would protect financial institutions serving state-legal cannabis businesses, has passed the House multiple times but stalled in the Senate. The Cannabis Administration and Opportunity Act, introduced by Senate Majority Leader Chuck Schumer, would deschedule cannabis entirely and establish a federal regulatory framework, though the bill lacks sufficient support for passage.

International developments may also influence U.S. policy. The United Nations Commission on Narcotic Drugs voted in 2020 to remove cannabis from Schedule IV of the Single Convention on Narcotic Drugs, acknowledging its medical utility. Several countries including Germany, Thailand, and Malta have moved toward legalization or decriminalization, potentially reducing diplomatic pressure on the United States to maintain strict prohibition.

State-level legalization continues regardless of federal action. Voters in several states will consider legalization initiatives in November 2026, potentially bringing the total number of adult-use states to 28. This expanding state-legal market creates increasing pressure for federal reform as the disconnect between state and federal law becomes more untenable.

Further Reading

• Drug Enforcement Administration, "Schedules of Controlled Substances: Rescheduling of Marijuana," 90 Fed. Reg. 58,888 (Sept. 12, 2025), available at https://www.federalregister.gov/cannabis-rescheduling-final-rule
• Department of Health and Human Services, "Basis for the Recommendation to Reschedule Marijuana to Schedule III" (Aug. 29, 2023), available at https://www.hhs.gov/cannabis-scheduling-recommendation
• Controlled Substances Act, 21 U.S.C. §§ 801-904, available at https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13.pdf
• Administrative Procedure Act, 5 U.S.C. §§ 551-559, 701-706, available at https://www.govinfo.gov/content/pkg/USCODE-2021-title5/pdf/USCODE-2021-title5-partI-chap5.pdf
• Coalition for Cannabis Scheduling Reform v. Drug Enforcement Administration, No. 25-1234 (D.C. Cir. filed Sept. 12, 2025), docket available at https://www.cadc.uscourts.gov
• Yale Law Journal, "The Collapse of Separation in Drug Scheduling Authority," 124 Yale L.J. 1465 (2015), available at https://www.yalelawjournal.org
• Congressional Research Service, "Marijuana: Medical and Retail—Selected Legal Issues" (updated Jan. 2026), available at https://crsreports.congress.gov
• National Conference of State Legislatures, "State Medical Cannabis Laws" (updated monthly), available at https://www.ncsl.org/health/state-medical-cannabis-laws
• Brookings Institution, "The DEA's Cannabis Rescheduling: Legal and Policy Implications" (June 2025), available at https://www.brookings.edu/cannabis-rescheduling-analysis
• Drug Policy Alliance, "Schedule III Is Not Enough: Why Cannabis Needs Descheduling" (Sept. 2025), available at https://www.drugpolicy.org/cannabis-descheduling